DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2026)

Biosimilars | Current Treatment | Immunology

Biosimilars | Current Treatment | Immunology

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Immune biologics including TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products and therefore offer a great opportunity for biosimilars developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s lucrative biologic Humira (adalimumab), which are available in Europe in October 2018, and biosimilars referencing Roche’s Rituxan/MabThera, which have already launched in Europe and are set to launch in the United States in Q3 2019. As the immune biosimilars space becomes increasingly competitive, it is important that manufacturers/marketers of biosimilars and branded biologics understand which factors influence physicians’ uptake. Decision Resources Group has conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights on physicians’ attitudes toward biosimilars, the drivers and barriers to biosimilar use, and the expectations for biosimilar adoption.

Questions answered:

  • Have physicians received recommendations to use biosimilars?
  • Are physicians switching patients from reference brands to biosimilars?
  • What factors do physicians consider when choosing among competing biosimilars?
  • How are TNF-alpha inhibitor and MAb biosimilars performing, and what are physicians’ expectations for their future uptake?
  • What are the key drivers and barriers to the uptake of TNF-alpha inhibitors and MAb biosimilars?

Scope:

  • Markets covered: France, Germany, and the United States.
  • Primary research: Survey of 90 rheumatologists and 91 gastroenterologists.

Key companies mentioned:

  • Amgen.
  • AbbVie.
  • Biogen.
  • Celltrion.
  • Johnson & Johnson/Janssen.
  • Merck & Co./MSD.
  • Mundipharma.
  • Novartis/Sandoz.
  • Pfizer/Hospira.
  • Roche/Genentech.
  • Samsung Bioepis.

Key drugs mentioned:

  • Inflectra (infliximab).
  • Remsima (infliximab).
  • Benepali (etanercept).
  • Flixabi (infliximab).
  • Truxima (rituximab).
  • Enbrel (etanercept).
  • Humira (adalimumab).
  • Remicade (infliximab).
  • Rituxan/MabThera (rituximab).
  • Simponi (golimumab).
  • Cimzia (certolizumab pegol).
  • Orencia (abatacept).
  • Actemra/RoActemra (tocilizumab).
  • Stelara (ustekinumab).
  • Entyvio (vedolizumab).

Table of contents

  • Immunology
    • Current Treatment: Biosimilars Immunology Report 2018
    • Webinar
      • December 2018
      • December 2018 Webinar

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): Hamzah Aideed, MSc
  • Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.  

Purchase Report

Recent reports:
You may also be interested in: